← Leaderboards
Ryan Cirz
Revagenix, Inc.
$40,209,479
Attributed
$40,209,479
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $17.9M · FY2020–24$20M$15M$10M$5M$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$40,209,479 · 2
By mechanism
N01$40,209,479 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Chemistry”
- John Damon Chodera · Sloan-Kettering Inst Can Research$48,839,180
- Bala Raja · Luminostics, Inc.$28,624,460
- Michael W Rabin · Florida State University$26,502,247
- Ross D McDonald · Florida State University$26,502,247
- Eric C Palm · Florida State University$26,502,247
- Jeffrey Glenn · Stanford University$26,017,226
Research focus
ChemistryEmerging Communicable DiseasesPre-ClinicalTherapeutic DevelopmentAdvanced DevelopmentTherapeutic CandidateResearch And DevelopmentProduct DevelopmentEfficacy EvaluationSafety AssessmentNational Institute Of Allergy And Infectious DiseaseBacterial Antibiotic ResistanceCategoriesPathway InteractionsPriority PathogenBacterial Drug ResistanceManufacturePseudomonas AeruginosaLead OptimizationPathogenCandidate SelectionBiodefenseResearch SupportBacterial Resistance
Grant awards (7)
Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases$11,270,810
N01 · FY2024 · AI · contact PI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$6,642,016
N01 · FY2024 · AI · contact PI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$5,121,040
N01 · FY2023 · AI · contact PI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$6,662,439
N01 · FY2022 · AI · contact PI
A NOVEL THERAPEUTIC WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY$4,798,925
N01 · FY2022 · AI · contact PI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$2,731,729
N01 · FY2021 · AI · contact PI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$2,982,520
N01 · FY2020 · AI · contact PI